Pfizer mines insurance data to see if its vaccine stops long COVID
NCT ID NCT05876377
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study looks at anonymous health records from California and Louisiana to see if the Pfizer-BioNTech COVID-19 vaccine helps prevent post-COVID conditions (long COVID). Researchers will also track who gets vaccinated. The study includes adults with a COVID-19 diagnosis between September 2024 and August 2025, using insurance claims and state vaccine registries.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can brain training zap long COVID brain fog?
- Brain fog after COVID: can two common drugs clear it?
- Could a five-day pill course cut COVID-19 deaths? czech nationwide data puts molnupiravir to the test.
- Can COVID-19 and emergency surgery be safely managed together? a massive hospital study seeks answers
- Text or call? study tests best way to boost COVID shots in schools
- Fish oil and Body's own healing molecules could lift long COVID depression